BST:1B3

Stock Analysis Report

Executive Summary

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally.


Snowflake Analysis

Flawless balance sheet and undervalued.

Share Price & News

How has BioSpecifics Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1B3's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

9.5%

1B3

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

-15.9%

1B3

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: 1B3 underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: 1B3 exceeded the German Market which returned -17.7% over the past year.


Shareholder returns

1B3IndustryMarket
7 Day9.5%11.2%7.3%
30 Day-6.1%-5.3%-17.9%
90 Day-7.3%-21.9%-25.8%
1 Year-15.9%-15.9%-4.9%-5.1%-15.1%-17.7%
3 Year-7.9%-7.9%17.7%16.5%-18.7%-25.6%
5 Year31.3%31.3%-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is BioSpecifics Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is BioSpecifics Technologies undervalued compared to its fair value and its price relative to the market?

30.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1B3 (€46) is trading below our estimate of fair value (€66.54)

Significantly Below Fair Value: 1B3 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1B3 is good value based on its PE Ratio (15.4x) compared to the Biotechs industry average (34x).

PE vs Market: 1B3 is good value based on its PE Ratio (15.4x) compared to the German market (16.4x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1B3's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1B3 is good value based on its PB Ratio (3x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is BioSpecifics Technologies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

58.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1B3's forecast earnings growth is above the savings rate (-0.4%).

Earnings vs Market: Insufficient data to determine if 1B3's earnings are forecast to grow faster than the German market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1B3's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 1B3's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 1B3's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has BioSpecifics Technologies performed over the past 5 years?

25.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1B3 has high quality earnings.

Growing Profit Margin: 1B3's current net profit margins (64.1%) are higher than last year (60.8%).


Past Earnings Growth Analysis

Earnings Trend: 1B3's earnings have grown significantly by 25.7% per year over the past 5 years.

Accelerating Growth: 1B3's earnings growth over the past year (22%) is below its 5-year average (25.7% per year).

Earnings vs Industry: 1B3 earnings growth over the past year (22%) exceeded the Biotechs industry 8.7%.


Return on Equity

High ROE: 1B3's Return on Equity (19.7%) is considered low.


Next Steps

Financial Health

How is BioSpecifics Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: 1B3's short term assets ($109.3M) exceed its short term liabilities ($1.4M).

Long Term Liabilities: 1B3's short term assets ($109.3M) exceed its long term liabilities ($739.7K).


Debt to Equity History and Analysis

Debt Level: 1B3 is debt free.

Reducing Debt: 1B3 has not had any debt for past 5 years.

Debt Coverage: 1B3 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 1B3 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: 1B3 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 1B3's debt is covered by short term assets.


Next Steps

Dividend

What is BioSpecifics Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1B3's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 1B3's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1B3's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1B3's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1B3's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.4yrs

Average management tenure


CEO

J. Buchi (64yo)

0.42

Tenure

Mr. J. Kevin Buchi serves as Director of Dicerna Pharmaceuticals, Inc. since August 16, 2018 and has been its Chairman since January 24, 2019. Mr. Buchi has been Chief Executive Officer of BioSpecifics Tec ...


Leadership Team

NamePositionTenureCompensationOwnership
J. Buchi
Chief Executive Officer0.42yrno datano data
Patrick Hutchison
Chief Financial Officer0.17yrno datano data
Patrick Caldwell
Principal Accounting Officerno datano datano data
Ronald Law
Senior Vice President of Business Development1.33yrsno datano data
Carl Valenstein
Corporate Secretaryno datano datano data

0.4yrs

Average Tenure

62yo

Average Age

Experienced Management: 1B3's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Paul Gitman
Independent Director30.17yrsUS$45.00k0.20% $696.7k
Michael Schamroth
Independent Director15.83yrsUS$45.00k1.55% $5.3m
Jennifer Chao
Independent Chairman of the Board0.42yrUS$340.15k0.00041% $1.4k
Toby Wegman
Director12.75yrsUS$22.00k12.75% $43.4m
Mark Wegman
Director12.75yrsUS$50.00k0.026% $87.8k

12.8yrs

Average Tenure

78yo

Average Age

Experienced Board: 1B3's board of directors are seasoned and experienced ( 12.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

BioSpecifics Technologies Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioSpecifics Technologies Corp.
  • Ticker: 1B3
  • Exchange: BST
  • Founded: 1957
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$377.843m
  • Listing Market Cap: US$340.777m
  • Shares outstanding: 7.34m
  • Website: https://www.biospecifics.com

Number of Employees


Location

  • BioSpecifics Technologies Corp.
  • Delaware Corporate Center II
  • 2 Righter Parkway
  • Wilmington
  • Delaware
  • 19803
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BSTCNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDNov 1991
1B3BST (Boerse-Stuttgart)YesCommon StockDEEURNov 1991

Biography

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren’s contracture and Peyronie’s disease under the XIAFLEX or Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, and human lipoma, as well as uterine fibroids. In addition, the company engages in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. BioSpecifics Technologies Corp. has a development and license agreement with Endo Global Ventures. The company was founded in 1957 and is headquartered in Wilmington, Delaware. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 23:22
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.